Pharmacokinetic and pharmacometabolomic study of pirfenidone in normal mouse tissues using high mass resolution MALDI-FTICR-mass spectrometry imaging

Histochemistry and Cell Biology

Volumn 145, Issue 2, 2016, Pages 201-211

  Sun, Na ^a   Fernandez, Isis E ^b   Wei, Mian ^a   Wu, Yin ^a   Aichler, Michaela ^a   Eickelberg, Oliver ^b   Walch, Axel ^a  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

5 Carboxy pirfenidone; 5 Hydroxymethyl pirfenidone; Idiopathic pulmonary fibrosis; Mass spectrometry imaging; Pharmacokinetics; Pharmacometabolomics; Pirfenidone

Indexed keywords

5 CARBOXY PIRFENIDONE; 5 HYDROXYMETHYL PIRFENIDONE; PIRFENIDONE; PYRIDINE DERIVATIVE; UNCLASSIFIED DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; PYRIDONE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CELL METABOLISM; CONTROLLED STUDY; DRUG HALF LIFE; FEMALE; HISTOLOGY; KIDNEY; LIVER; LUNG; LUNG PARENCHYMA; MALDI FTICR MSI; MASS SPECTROMETER; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; METABOLITE; METABOLOME; METABOLOMICS; MOLECULAR IMAGING; MOUSE; NONHUMAN; PHARMACOKINETIC PARAMETERS; PHARMACOMETABOLOMICS; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; TIME TO MAXIMUM PLASMA CONCENTRATION; TISSUE DISTRIBUTION; TISSUE SECTION; ANIMAL; C57BL MOUSE; CHEMISTRY; MATRIX-ASSISTED LASER DESORPTION-IONIZATION MASS SPECTROMETRY; METABOLISM;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; FEMALE; KIDNEY; LIVER; LUNG; MICE; MICE, INBRED C57BL; PYRIDONES; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TISSUE DISTRIBUTION;

EID: 84957841049     PISSN: 09486143     EISSN: 1432119X     Source Type: Journal    
DOI: 10.1007/s00418-015-1382-7     Document Type: Article

References (38)

1. Balluff B, Schone C, Hofler H, Walch A (2011) MALDI imaging mass spectrometry for direct tissue analysis: technological advancements and recent applications. Histochem Cell Biol 136:227–244. doi:10.1007/s00418-011-0843-x
2. Bruss ML, Margolin SB, Giri SN (2004) Pharmacokinetics of orally administered pirfenidone in male and female beagles. J Vet Pharmacol Ther 27:361–367. doi:10.1111/j.1365-2885.2004.00612.x
3. Bruss ML, Stanley SD, Margolin SB, Giri SN (2008) Pharmacokinetics and metabolism of intravenous pirfenidone in sheep. Biopharm Drug Dispos 29:119–126. doi:10.1002/bdd.595
4. Buck A et al (2015) High-resolution MALDI-FT-ICR MS imaging for the analysis of metabolites from formalin-fixed paraffin-embedded clinical tissue samples. J Pathol. doi:10.1002/path.4560
5. Castellino S, Groseclose MR, Wagner D (2011) MALDI imaging mass spectrometry: bridging biology and chemistry in drug development. Bioanalysis 3:2427–2441. doi:10.4155/bio.11.232
6. Clayton TA et al (2006) Pharmaco-metabonomic phenotyping and personalized drug treatment. Nature 440:1073–1077. doi:10.1038/nature04648
7. Cornett DS, Frappier SL, Caprioli RM (2008) MALDI-FTICR imaging mass spectrometry of drugs and metabolites in tissue. Anal Chem 80:5648–5653. doi:10.1021/ac800617s
8. Edwards JL, Kennedy RT (2005) Metabolomic analysis of eukaryotic tissue and prokaryotes using negative mode MALDI time-of-flight mass spectrometry. Anal Chem 77:2201–2209. doi:10.1021/ac048323r
9. Ellero-Simatos S et al (2014) Pharmacometabolomics reveals that serotonin is implicated in aspirin response variability. CPT Pharmacom Syst Pharmacol 3:e125. doi:10.1038/psp.2014.22
10. Fernandez IE, Eickelberg O (2012) New cellular and molecular mechanisms of lung injury and fibrosis in idiopathic pulmonary fibrosis. Lancet 380:680–688. doi:10.1016/S0140-6736(12)61144-1
11. Giri SN, Wang Q, Xie Y, Lango J, Morin D, Margolin SB, Buckpitt AR (2002) Pharmacokinetics and metabolism of a novel antifibrotic drug pirfenidone, in mice following intravenous administration. Biopharm Drug Dispos 23:203–211. doi:10.1002/bdd.311
12. Iyer SN, Gurujeyalakshmi G, Giri SN (1999) Effects of pirfenidone on transforming growth factor-beta gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J Pharmacol Exp Ther 291:367–373
13. Kallback P, Shariatgorji M, Nilsson A, Andren PE (2012) Novel mass spectrometry imaging software assisting labeled normalization and quantitation of drugs and neuropeptides directly in tissue sections. J Proteomics 75:4941–4951. doi:10.1016/j.jprot.2012.07.034
14. Kashikar V, Dhole S, Kandekar U, Khose P (2014) Study of mucoadhesive microsphere of pirfenidone for nasal drug delivery. Asian J Pharm 8:43–50
15. King TE Jr, Pardo A, Selman M (2011) Idiopathic pulmonary fibrosis. Lancet 378:1949–1961. doi:10.1016/S0140-6736(11)60052-4
16. King TE Jr et al (2014) A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 370:2083–2092. doi:10.1056/NEJMoa1402582
17. Lee MS, Kerns EH (1999) LC/MS applications in drug development. Mass Spectrom Rev 18:187–279. doi:10.1002/(SICI)1098-2787(1999)18:3/4<187:AID-MAS2>3.0.CO;2-K
18. Mantini D et al (2007) LIMPIC: a computational method for the separation of protein MALDI-TOF-MS signals from noise. BMC Bioinform 8:101. doi:10.1186/1471-2105-8-101
19. McDonnell LA, van Remoortere A, de Velde N, van Zeijl RJ, Deelder AM (2010) Imaging mass spectrometry data reduction: automated feature identification and extraction. J Am Soc Mass Spectrom 21:1969–1978. doi:10.1016/j.jasms.2010.08.008
20. Miric G, Dallemagne C, Endre Z, Margolin S, Taylor SM, Brown L (2001) Reversal of cardiac and renal fibrosis by pirfenidone and spironolactone in streptozotocin-diabetic rats. Br J Pharmacol 133:687–694. doi:10.1038/sj.bjp.0704131
21. Miura D, Fujimura Y, Tachibana H, Wariishi H (2010a) Highly sensitive matrix-assisted laser desorption ionization-mass spectrometry for high-throughput metabolic profiling. Anal Chem 82:498–504. doi:10.1021/ac901083a
22. Miura D, Fujimura Y, Yamato M, Hyodo F, Utsumi H, Tachibana H, Wariishi H (2010b) Ultrahighly sensitive in situ metabolomic imaging for visualizing spatiotemporal metabolic behaviors. Anal Chem 82:9789–9796. doi:10.1021/ac101998z
23. Mouton JW, Theuretzbacher U, Craig WA, Tulkens PM, Derendorf H, Cars O (2008) Tissue concentrations: do we ever learn? J Antimicrob Chemother 61:235–237. doi:10.1093/jac/dkm476
24. Nalysnyk L, Cid-Ruzafa J, Rotella P, Esser D (2012) Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature. Eur Respir Rev 21:355–361. doi:10.1183/09059180.00002512
25. Noble PW et al (2011) Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 377:1760–1769. doi:10.1016/S0140-6736(11)60405-4
26. Norris JL, Caprioli RM (2013) Analysis of tissue specimens by matrix-assisted laser desorption/ionization imaging mass spectrometry in biological and clinical research. Chem Rev 113:2309–2342. doi:10.1021/cr3004295
27. Pirman DA, Kiss A, Heeren RM, Yost RA (2013) Identifying tissue-specific signal variation in MALDI mass spectrometric imaging by use of an internal standard. Anal Chem 85:1090–1096. doi:10.1021/ac3029618
28. Raghu G et al (2011) An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183:788–824. doi:10.1164/rccm.2009-040GL
29. Römpp A, Guenther S, Takats Z, Spengler B (2011) Mass spectrometry imaging with high resolution in mass and space (HR(2) MSI) for reliable investigation of drug compound distributions on the cellular level. Anal Bioanal Chem 401:65–73. doi:10.1007/s00216-011-4990-7
30. Schaefer CJ, Ruhrmund DW, Pan L, Seiwert SD, Kossen K (2011) Antifibrotic activities of pirfenidone in animal models. Eur Respir Rev 20:85–97. doi:10.1183/09059180.00001111
31. Shi S, Wu J, Chen H, Chen H, Wu J, Zeng F (2007) Single- and multiple-dose pharmacokinetics of pirfenidone, an antifibrotic agent, in healthy Chinese volunteers. J Clin Pharmacol 47:1268–1276. doi:10.1177/0091270007304104
32. Shroff R, Muck A, Svatos A (2007) Analysis of low molecular weight acids by negative mode matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Rapid Commun Mass Spectrom 21:3295–3300. doi:10.1002/rcm.3216
33. Sun N et al (2014) High-resolution metabolite imaging of light and dark treated retina using MALDI-FTICR mass spectrometry. Proteomics 14:913–923. doi:10.1002/pmic.201300407
34. Togami K, Kanehira Y, Tada H (2013) Possible involvement of pirfenidone metabolites in the antifibrotic action of a therapy for idiopathic pulmonary fibrosis. Biol Pharm Bull 36:1525–1527
35. Walch A, Rauser S, Deininger SO, Hofler H (2008) MALDI imaging mass spectrometry for direct tissue analysis: a new frontier for molecular histology. Histochem Cell Biol 130:421–434. doi:10.1007/s00418-008-0469-9
36. Wang Y, Zhao X, Zhong J, Chen Y, Liu X, Wang G (2006) Simple determination of pirfenidone in rat plasma via high-performance liquid chromatography. Biomed Chromatogr 20:1375–1379. doi:10.1002/bmc.708
37. Wikoff WR et al (2013) Pharmacometabolomics reveals racial differences in response to atenolol treatment. PLoS ONE 8:e57639. doi:10.1371/journal.pone.0057639
38. Zhao XY, Zeng X, Li XM, Wang TL, Wang BE (2009) Pirfenidone inhibits carbon tetrachloride- and albumin complex-induced liver fibrosis in rodents by preventing activation of hepatic stellate cells. Clin Exp Pharmacol Physiol 36:963–968. doi:10.1111/j.1440-1681.2009.05194.x